Lingfei Wang
Hangzhou, 310013, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Up-regulated FNDC1 accelerates stemness and chemoradiation resistance in colorectal cancer cells.
Journal: Biochemical and biophysical research communications
Published: December 09, 2021
A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: May 09, 2021
Apaf-1/caspase-4 pyroptosome: a mediator of mitochondrial permeability transition-triggered pyroptosis.
Journal: Signal transduction and targeted therapy
Published: January 09, 2021
Downregulation of miR-423-5p Contributes to the Radioresistance in Colorectal Cancer Cells.
Journal: Frontiers in oncology
Published: July 11, 2020
Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells.
Journal: Oncology letters
Published: March 12, 2020
Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report.
Journal: Frontiers in oncology
Published: February 10, 2020
Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.
Journal: Drug design, development and therapy
Published: January 03, 2020
The function of SOX2 in breast cancer and relevant signaling pathway.
Journal: Pathology, research and practice
Published: September 02, 2019
The antimicrobial peptide PFR induces necroptosis mediated by ER stress and elevated cytoplasmic calcium and mitochondrial ROS levels: cooperation with Ara-C to act against acute myeloid leukemia.
Journal: Signal transduction and targeted therapy
Published: August 14, 2019
The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.
Journal: Oncotarget
Published: March 07, 2017
Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody.
Journal: Molecular immunology
Published: January 06, 2017
Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody.
Journal: Oncotarget
Published: December 16, 2016
Last Updated: 09/26/2026